INVOKANA (canagliflozin) Significantly Improved Renal Outcomes and...
Raritan, N.J., and New Orleans, November 3, 2017 – Janssen Research & Development, LLC today announced additional analyses from the landmark CANVAS clinical trial program showing INVOKANA®...
View ArticleSTELARA (USTEKINUMAB) SHOWS POSITIVE RESULTS IN TREATMENT OF SYSTEMIC LUPUS...
STELARA® showed significant reductions in lupus disease activity vs. read more
View ArticleNEW PHASE 2 DATA SHOW TREATMENT WITH TREMFYA (GUSELKUMAB) IMPROVED PSORIATIC...
San Diego, CA, November 7, 2017 ― Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective...
View ArticleINVOKANA (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in...
RARITAN, N.J. and ANAHEIM, Calif., November 14, 2017 – Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA® (canagliflozin)...
View ArticleEASEL is the first real-world study to show adults with type 2 diabetes and...
TITUSVILLE, NJ, November 17, 2017 – A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated therapy with INVOKANA®...
View ArticleSupplemental Biologics License Application (sBLA) seeks first indication for...
RARITAN, NJ, November 21, 2017 – Janssen Biotech, Inc. read more
View ArticleJohnson & Johnson and Partners Announce First Efficacy Study for...
New Brunswick, NJ, 30 November 2017 – On the eve of World AIDS Day (December 1) Johnson & Johnson announced that its Janssen Pharmaceutical Companies together with a consortium of global partners...
View ArticleClinical efficacy trial of Ragon Institute-supported HIV vaccine underway in...
Mosaic” vaccine designed to respond to many viral strains, address challenge of genetic diversity. read more
View ArticlePhase 3 Study Evaluating IMBRUVICA (ibrutinib) in Combination with Rituximab...
RARITAN, NJ, December 5, 2017 – Janssen Research & Development, LLC (Janssen) announced that the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA® (ibrutinib) in combination with rituximab...
View ArticleSustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma...
ATLANTA and RARITAN, NJ, Dec. 9, 2017 – Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients...
View ArticleViiV Healthcare to progress collaboration with Janssen to develop the first...
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. read more
View ArticleAmerican Diabetes Association Thanks the 2016 Principal Officers and Welcomes...
The American Diabetes Association (Association), the nation’s largest voluntary health organization leading the fight to Stop Diabetes®, thanks the four Principal Officers whose terms of leadership...
View ArticleViiV Healthcare announces detailed positive phase III results for...
In the SWORD studies, the two-drug regimen showed comparable efficacy to three- or four-drug regimensin virologically suppressed patients. read more
View ArticleMulti-sector partnership supports detection and treatment of childhood...
Nghe An, Vietnam, November 14, 2017—Increasing numbers of children in four districts of Vietnam’s Nghe An province are being protected against tuberculosis (TB) through a partnership focused on...
View ArticleNIH and partners launch HIV vaccine efficacy study
Public-private partnership begins clinical trial in sub-Saharan Africa. read more
View ArticleJanssen Submits Supplemental New Drug Application to FDA Seeking New...
RARITAN, NJ, December 11, 2017 – Janssen Research & Development, LLC (Janssen) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...
View ArticleEarly data evaluated subcutaneous delivery of DARZALEX in relapsed or...
ATLANTA and RARITAN, N.J., December 11, 2017 – Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery...
View ArticleDARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes...
ATLANTA and RARITAN, N.J., December 12, 2017 – Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX® (daratumumab) in combination with...
View ArticleJanssen and Leading Advocacy Organizations Introduce Cancer.com, a...
HORSHAM, Pa., December 13, 2017 – The Janssen Pharmaceutical Companies of Johnson & Johnson are proud to announce the launch of Cancer.com, an online destination providing those impacted by cancer...
View ArticleU.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for...
Horsham, PA, December 21, 2017 – Janssen Biotech, Inc. read more
View Article
